BOSTON, MA — Lumanity today announced its contribution to a peer-reviewed analysis published in Blood Advances, the journal of the American Society of Hematology. The study, developed alongside Blood Cancer United® (formerly The Leukemia & Lymphoma Society) and the Clara D. Bloomfield Center for Leukemia Outcomes Research at The Ohio State University Comprehensive Cancer Center, introduces a new methodology for measuring what 75 years of blood cancer treatment advances have delivered to patients: life-years saved.
Dennis Chang, PhD, Senior Vice President of Strategy Consulting at Lumanity, served as a co-author, building on integral analytical groundwork laid by Michael Rice and Sydney Morris of Lumanity. Dennis works at the intersection of oncology science and strategic decision-making, helping biopharma teams translate complex evidence into defensible choices across indication prioritization, portfolio strategy, and asset development.
“Five-year survival rates and mortality statistics tell part of the story. Life-years saved tells you what innovation returned to patients and families, and where the gaps still are,” said Chang. “That kind of quantifiable, reproducible framework matters when decisions about research investment, access, and equity need to hold up under scrutiny.”
Read the full study and consider what the evidence means for where the field invests next.
Read the full study in Blood Advances
Study Contributors: This analysis was developed and conducted by researchers from Blood Cancer United and Clara D. Bloomfield Center for Leukemia Outcomes Research at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute in conjunction with Lumanity.
About Blood Cancer United®
Blood Cancer United® (formerly The Leukemia & Lymphoma Society) is the largest global nonprofit focused on blood cancer patient support, research, and advocacy. Since their founding in 1949, the organization has consistently evolved to better serve people affected by all 100-plus types of blood cancer. Blood Cancer United funds innovative research, offers free resources and personalized support, and advocates at state and national levels for more accessible and affordable healthcare for all patients. To learn more, visit www.BloodCancerUnited.org.
About Lumanity
Lumanity is a leading global strategic partner for biopharmaceutical companies, engineering breakthrough value to transform lives. We combine deep scientific, clinical, medical, regulatory, and commercial expertise with advanced technology and AI-driven tools to guide decisions and execution across the entire medicine value creation journey. With 1,200 experts conducting work in over 50 countries, we serve leading pharmaceutical and biotech companies worldwide, integrating strategy, evidence, engagement, and technology to accelerate and optimize access to life-changing medicines.
